Top

Cancer Chemotherapy and Pharmacology

Published in:

01-08-2008 | Original Article

Relationship of peripheral blood CD4-positive T cells to carcinogenesis in patients with HCV-related chronic hepatitis and liver cirrhosis

Authors: Teppei Matsui, Hidenari Nagai, Yasukiyo Sumino, Kazumasa Miki

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2008

Abstract

Introduction

It has been reported that Th2 cytokines down-regulate antitumor immunity, while activation of type 1 T cell responses promotes antitumor immunity. However, detailed information on the immunological background of patients with HCC is still unknown. The objectives of this study were to evaluate the Th1/Th2 balance and to investigate the relation between carcinogenesis and host immunity in patients with chronic hepatitis C, HCV-related liver cirrhosis (LC), or HCC.

Patients/methods

The study population was 117 patients who had chronic inflammation due to HCV infection diagnosed from pathological examination of liver biopsy specimens, including 32 patients who had HCV-related LC with HCC. Apart from the patients with HCC, they were divided into the four subgroups based on the fibrosis score of Desment (stages 1–4). Blood samples were collected in the early morning before treatment. Flow cytometry was used to assess cytoplasmic IFN-gamma and IL-4 expression by peripheral blood CD4+ T cells, and the percentage of IFN-gamma+ and IL4− T cells (Th1) or IFN-gamma- and IL4+ T cells (Th2) was calculated before the start of each therapy.

Results

There were 20 patients in F1, 25 patients in F2, 19 patients in F3, 21 patients in F4, and 32 patients with HCC. In the F4 and HCC groups, Th1 cells tended to increase depending on the extent of fibrosis, although there were no significant differences between these groups and the other groups. In the HCC group, Th2 cells showed a significantly higher percentage than in the F1 or F3 groups.

Conclusions

These results suggest that Th1 dominance is lost due to an increase of Th2 cells in HCC patients and that carcinogenesis might occur in patients with chronic HCV infection and increased level of Th2 cells.

Wada Y, Nakashima O, Kutani R, Yamamoto O, Kojiro M (1998) Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27:407–414PubMedCrossRef

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montaltof F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334:693–700PubMedCrossRef

Schirren CA, Jung M, Worzfeld T, Mamin M, Baretton GB, Gruener NH, Gerlach JT, Diepolder HM, Zachoval R, Pape GR (2000) Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation. Liver Transplant 6:222–228

Marinos G, Rossol S, Carucci O, Wong PY, Danaldson P, Hussain MJ, Vergani D, Portmann BC, Williams R, Naoumov NV (2000) Immunopathogenesis of hepatitis B virus recurrence after liver transplantation. Transplantation 69:559–568PubMedCrossRef

Mosmann TR, Coffman RL (1989) Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145–173PubMedCrossRef

O’Garra A (1998) Cytokines induce the development of functionally heterogenous T helper cell subsets. Immunity 8:275–283PubMedCrossRef

Vincent MS, Gumperz JE, Brenner MB (2003) Understanding the function of CD1d-restricted T cells. Nat Immunol 6:517–523CrossRef

Nakajima H, Mizushima N, Kanai K (1987) Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver. Jpn J Clin Oncol 17:327–332PubMed

Kobayashi M, Kobayashi H, Polland RB, Suzuki F (1998) A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160:5869–5873PubMed

10.

Zitvogel L, Mayordomo JI, Tjandrawan T, Deleo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87–97PubMedCrossRef

11.

Tsung K, Meko JB, Peplinski GR, Norton JA (1997) IL-12 induces T helper 1-directed antitumor response. J Immunol 158:3359–3365PubMed

12.

Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM (1997) Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94:10833–10837PubMedCrossRef

13.

Hu H-M, Urba WJ, Fox BA (1998) Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 161:3033PubMed

14.

Shinohara M, Ishii K, Takamura N, Takamura N (2003) Long-term changes of peripheral blood CD4-positive T cell subsets (Th1, Th2) in chronic hepatitis C patients with a sustained response no response to IFN. Hepatol Res 27:260–265PubMedCrossRef

15.

Jung T, Schauer U, Heusser C, Neumann C, Rieger C (1993) Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159:197–207PubMedCrossRef

16.

Kaser T, Enrich B, Ludwiczek O, Vogel W, Tilg H (1999) Interferon-alpha (INF-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway. Clin Exp Immunol 118:71–77PubMedCrossRef

17.

Fang SH, Hwang LH, Chen DS, Chiang BL (2000) Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 33:791–798PubMedCrossRef

18.

Takamura N, Ishii K, Shinohara M, Matsumaru K, Kawafune T, Sumino Y (2002) Analysis of peripheral blood CD4 positive T cells using intracellular staining method in paients with chronic hepatitis C. J Med Soc Toho 49(1):45–52

19.

Cao Z, Chen X, Wu Z (2007) Effect of splenectomy in patients with cirrhosis undergoing hepatic resection for hepatocellular carcinoma. World J Gastroenterol 13(2):280–284

20.

Sakaguchi E, Kayano K, Segawa M, Okamoto M, Sakaida I, Okita K (2002) Th1 down-regulation at the single-lymphocyte level in HCV-related liver cirrhosis and the effect of TGF-β on Th1 response: possible implication for the development of hepatoma. Hepatol Res 24:282–289PubMedCrossRef

21.

Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T (2001) Dysfunction of T cell receptor Vα24Jα18+, vβ??+(double-negative regulatory natural killer T cells in autoimmune disease. Arthritis Rheum 44:1127–1136PubMedCrossRef

22.

Kita H, Imawari M, Gershwin ME (2004) Cellular immune response in primary bilialy cirrhosis. Hepatol Res 28:12–17PubMedCrossRef

23.

Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K (2000) Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 97:5498–5503PubMedCrossRef

24.

Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura(N, Akutsu Y, Motohashi S, Iizawa T, Endo H, Fujisawa T, Shinkai H, Taniguchi M (1999) Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res 59:5102–5105PubMed

25.

Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE, O’Farrelly C (1999) The human liver contains multiple population of NK cells, T cells, and CD3 + CD56+ natural T cell with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 163:2314–2321PubMed

26.

Tartter PA, Steinberg B, Barron DM, Martinelli G (1987) The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 122:1264–1268PubMed

27.

Exley MA, He Q, Cheng O, Wang RJ, Cheney CP, Balk SP, Kuziel MJ (2002) Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol 168:1519–1523PubMed

28.

Poccia F, Agrati C (2003) Intrahepatic natural immunity and HCV immunopathogenesis. Cell Death Differ 10:S9–S12PubMedCrossRef

Title: Relationship of peripheral blood CD4-positive T cells to carcinogenesis in patients with HCV-related chronic hepatitis and liver cirrhosis
Authors: Teppei Matsui
Hidenari Nagai
Yasukiyo Sumino
Kazumasa Miki
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0618-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Patients/methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2008

Influence of carboplatin infusion on osteosarcoma blood flow

Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N 1 , N 11 diethylnorspermine

4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-Jun for cancer therapy

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates

Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer